Complete Wegovy vs Mounjaro Comparison: Mechanisms & Pricing
Wegovy 1.7mg Equivalent to Mounjaro: True Cost Transparency
When comparing Wegovy 1.7mg equivalent to Mounjaro doses, hidden fees can dramatically impact your treatment budget. Unlike competitors who charge separate consultation fees (£30-50), prescription charges (£20-30), and administration costs, EverydayMeds provides complete price transparency. Our Wegovy 1.7mg at £139.99 includes everything: your clinical assessment, MHRA-approved prescriber review, the prescription-only medicine itself, and temperature-controlled delivery. This approach eliminates the frustration of discovering additional charges at checkout.
The equivalent therapeutic progression with Mounjaro follows a different dosing schedule, but our transparent pricing philosophy remains identical. Whether you're prescribed Wegovy 1.7mg or the equivalent Mounjaro dose, what you see is what you pay. Our GPhC-registered pharmacy (#9012878) ensures both medications receive the same professional oversight and storage standards, with pricing that reflects true value rather than hidden profit margins.
Wegovy 1.7mg vs Mounjaro: Detailed Pricing Structure
Understanding Wegovy 1.7mg equivalent to Mounjaro requires examining both single pen costs and progression bundles. Our Consistency 1.7mg bundle (two pens) costs £309.99, providing eight weeks of treatment at this dose level. For patients considering the transition to maintenance, our Elevate Duo (1.7mg plus 2.4mg) costs £369.99, covering the complete progression to your target dose. These bundles offer Reliable Supply continuity without price fluctuations.
Returning customers maximise value through the DOSE25 code, whilst new patients benefit from FIRST40 pricing. The equivalent Mounjaro progression follows different milligram strengths but identical transparent pricing principles. Both medications are available through our streamlined assessment process, with express prescriber review available within 24 hours for £20 additional – clearly stated, never hidden. This optional upgrade represents our only supplementary charge, maintaining our commitment to pricing transparency.
Clinical Evidence: Wegovy 1.7mg Therapeutic Profile
Wegovy 1.7mg represents the penultimate dose in your escalation journey, with clinical trials demonstrating progressive efficacy improvements at higher doses. The STEP 1 trial showed patients achieving approximately 15% average weight loss at 68 weeks when using the full Wegovy dose progression alongside diet and exercise modifications. This 1.7mg dose bridges the gap between initial therapeutic response and maintenance therapy.
When comparing Wegovy 1.7mg equivalent to Mounjaro responses, both medications demonstrate significant efficacy in clinical trials, though direct head-to-head comparisons require careful interpretation due to different trial designs and patient populations. The Wilding et al. NEJM 2021 study established Wegovy's cardiovascular safety profile alongside its weight management benefits. Both treatments are available through EverydayMeds with identical assessment standards.
Mechanism Comparison: Wegovy 1.7mg vs Mounjaro Equivalents
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormones to regulate appetite and glucose metabolism. At 1.7mg, this dose provides substantial GLP-1 activation, promoting satiety after smaller meals and reducing food cravings through central nervous system appetite centres. Mounjaro contains tirzepatide, functioning as a dual GIP/GLP-1 receptor agonist, potentially offering enhanced metabolic effects through this dual pathway activation. Both medications require dose escalation protocols and work most effectively alongside reduced-calorie diets and increased physical activity. The choice between Wegovy 1.7mg and equivalent Mounjaro doses depends on individual response patterns, tolerability profiles, and prescriber assessment of optimal therapeutic approach.
Streamlined Ordering: From Assessment to Delivery
Accessing Wegovy 1.7mg or equivalent Mounjaro doses through EverydayMeds begins with our 3-minute online clinical assessment, designed to capture essential medical history and current health status. This information undergoes review by MHRA-approved prescribers within 3 working days (or 24 hours with express service), ensuring appropriate prescribing standards for these prescription-only medicines. Upon approval, your medication ships via next-day delivery using specialised cold-chain transport to maintain optimal storage conditions. Our GPhC-registered pharmacy (#9012878) coordinates every step, from initial assessment through final delivery, maintaining professional oversight throughout your treatment journey. This integrated approach eliminates multiple provider coordination whilst ensuring clinical safety standards.
Storage and Practical Considerations for Wegovy 1.7mg
Wegovy 1.7mg arrives in the FlexTouch pen format, requiring refrigerated storage between 2-8°C before first use, with the advantage of remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration. This extended room temperature stability provides superior travel convenience compared to Mounjaro's 21-day limit, particularly important for patients with active lifestyles or frequent travel commitments. Each pen delivers four weekly doses, with your 1.7mg dose representing weeks 13-16 of your escalation protocol before advancing to the 2.4mg maintenance dose. Proper injection technique and site rotation help optimise absorption and minimise injection site reactions. The pre-filled pen design eliminates dosing errors whilst the dose escalation schedule allows your body to adjust gradually to increasing semaglutide levels.
Cost Predictability: Wegovy 1.7mg Long-Term Planning
Patients comparing Wegovy 1.7mg equivalent to Mounjaro often prioritise cost predictability for long-term treatment planning. Our transparent pricing eliminates budget uncertainty, with clearly stated costs for each dose level and bundle option. Unlike subscription models with automatic renewals or hidden price increases, each order represents a discrete transaction with fixed pricing. Many competitors implement tiered consultation fees or loyalty programs with complex terms that obscure true costs.
For patients approaching the 1.7mg dose level, maintenance planning becomes crucial since weight management typically requires ongoing treatment. Our Ultimate Stability Trio (three 2.4mg pens) costs £649.99, providing three months of maintenance therapy with complete price visibility. This transparency enables informed financial planning whilst ensuring treatment continuity without supply interruptions or unexpected cost fluctuations.
Expert Guidance: Wegovy 1.7mg Treatment Decisions
Choosing between Wegovy 1.7mg and equivalent Mounjaro options requires expert clinical assessment of your individual response pattern, side effect profile, and treatment objectives. Our prescriber team evaluates factors including current dose tolerance, weight loss trajectory, and any emerging side effects to optimise your treatment approach. Both Wegovy and Mounjaro are available from EverydayMeds – your prescriber can help determine which medication aligns best with your therapeutic needs. This personalised approach ensures appropriate medication selection whilst maintaining our commitment to transparent pricing and professional clinical oversight. New customers can begin their assessment today using code FIRST40, whilst returning customers continue with DOSE25 for optimal value. Visit https://everydaymeds.co.uk/products/wegovy-1-7mg to start your clinical assessment and benefit from our comprehensive transparent pricing approach.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
